147 related articles for article (PubMed ID: 27139481)
1. Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.
Chen H; Li C; Zemlicka J; Gentry BG; Bowlin TL; Coen DM
Antimicrob Agents Chemother; 2016 Jul; 60(7):4176-82. PubMed ID: 27139481
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.
Gentry BG; Drach JC
Antimicrob Agents Chemother; 2014; 58(4):2329-33. PubMed ID: 24514084
[TBL] [Abstract][Full Text] [Related]
3. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
[TBL] [Abstract][Full Text] [Related]
4. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
5. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
James SH; Hartline CB; Harden EA; Driebe EM; Schupp JM; Engelthaler DM; Keim PS; Bowlin TL; Kern ER; Prichard MN
Antimicrob Agents Chemother; 2011 Oct; 55(10):4682-91. PubMed ID: 21788463
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
7. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
Tenney DJ; Yamanaka G; Voss SM; Cianci CW; Tuomari AV; Sheaffer AK; Alam M; Colonno RJ
Antimicrob Agents Chemother; 1997 Dec; 41(12):2680-5. PubMed ID: 9420038
[TBL] [Abstract][Full Text] [Related]
8. Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.
Gentry BG; Vollmer LE; Hall ED; Borysko KZ; Zemlicka J; Kamil JP; Drach JC
Antimicrob Agents Chemother; 2013 Sep; 57(9):4343-8. PubMed ID: 23817384
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir.
Gentry BG; Kamil JP; Coen DM; Zemlicka J; Drach JC
Antimicrob Agents Chemother; 2010 Aug; 54(8):3093-8. PubMed ID: 20547817
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inhibition of human cytomegalovirus replication by oxetanocin G.
Daikoku T; Yamamoto N; Saito S; Kitagawa M; Shimada N; Nishiyama Y
Biochem Biophys Res Commun; 1991 Apr; 176(2):805-12. PubMed ID: 1851005
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of herpes simplex virus type 1 DNA polymerase by [1R(1 alpha,2 beta,3 alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine.
Terry BJ; Cianci CW; Hagen ME
Mol Pharmacol; 1991 Oct; 40(4):591-6. PubMed ID: 1656194
[TBL] [Abstract][Full Text] [Related]
12. Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants.
Baldanti F; Sarasini A; Drach JC; Zemlicka J; Gerna G
Antiviral Res; 2002 Dec; 56(3):273-8. PubMed ID: 12406510
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity.
Chen H; Beardsley GP; Coen DM
Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17462-7. PubMed ID: 25422422
[TBL] [Abstract][Full Text] [Related]
14. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.
Prichard MN; Williams JD; Komazin-Meredith G; Khan AR; Price NB; Jefferson GM; Harden EA; Hartline CB; Peet NP; Bowlin TL
Antimicrob Agents Chemother; 2013 Aug; 57(8):3518-27. PubMed ID: 23669381
[TBL] [Abstract][Full Text] [Related]
16. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
Hussein ITM; Brooks J; Bowlin TL
Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
Chou S; Bowlin TL
Antimicrob Agents Chemother; 2011 Jan; 55(1):382-4. PubMed ID: 21041510
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase.
Gentry BG; Gentry SN; Jackson TL; Zemlicka J; Drach JC
Biochem Pharmacol; 2011 Jan; 81(1):43-9. PubMed ID: 20846508
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.
Biron KK; Harvey RJ; Chamberlain SC; Good SS; Smith AA; Davis MG; Talarico CL; Miller WH; Ferris R; Dornsife RE; Stanat SC; Drach JC; Townsend LB; Koszalka GW
Antimicrob Agents Chemother; 2002 Aug; 46(8):2365-72. PubMed ID: 12121906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
